RxDoctor Payments Data

Sterling Riddley, MD

Family Medicine · Fayetteville, NCNPI 1902288111

Payments from drug & device makers

$983in general payments, 2019–2025

Across 26 payments — averaging $37.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$251
  • Insulet Corporation$216
  • Medtronic$165
  • Corcept Therapeutics$161
  • Ascensia Diabetes Care US Inc.$40
  • Sequel Med Tech, LLC$32
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$91893%
  • Education$657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$983 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,390
Medicare patients
261
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide228$355,171
JardianceEmpagliflozin217$236,682
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7102$171,941
MounjaroTirzepatide127$164,686
TrulicityDulaglutide79$160,819
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt72$99,746
RybelsusSemaglutide53$94,781
Humulin R U-500Insulin Regular, Human38$64,854
FarxigaDapagliflozin Propanediol54$59,869
Soliqua 100-33Insulin Glargine/Lixisenatide35$54,839
JanuviaSitagliptin Phosphate36$47,581
ShingrixVaricella-Zoster Ge/As01b/Pf164$36,155
Lantus SolostarInsulin Glargine,hum.Rec.Anlog165$29,060
Humalog Kwikpen U-200Insulin Lispro19$28,931
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$27,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$251$469,056318 claims
MerckJanuvia, Janumet$21$54,04848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →